The United Kingdom Blood Disease Industry Outlook 2022 - 2026

Key Market Indicators

Sales of blood and blood forming organs medicines in the UK are expected to reach £1.6 billion by 2026, up from £1.4 billion in 2021, representing a 2.2% year-on-year average growth rate. Since 2000, sales in the UK have increased at a rate of 6.4% each year. In 2021, the UK was the sixth largest market, overtaken by Spain at £1.4 billion. Germany, Italy and South Korea respectively were ranked second, third and fourth. The prevalence of anemia in the UK is set to reach 62,310 hospital discharges by 2026, up from 60,020 in 2021, a 0.6% year-on-year CAGR. Since 2005, UK demand has grown by 1.5% each year. In 2021, Germany took the lead with 60,020 hospital discharges, with the UK, Germany and Poland ranked second, third and fourth respectively.

The United Kingdom Blood Disease Market Data and Forecasts

Improve your Knowledge with the latest Indicators and Trends

• Pharmaceutical Advances: A Comprehensive Review of Sickle Cell Disease Pipeline Development

  Sickle cell disease (SCD) pharmaceutical landscape has significantly evolved over the past years, primarily driven by a greater understanding of the disease pathology and emerging innovative therapeutic paradigms. The shift towards patient-specific treatments, and the introduction of gene therapy and genome editing as potential curative options are remarkable indicators of...

  Discover more insights

• Molecular Blood Typing and Infectious Disease Markets: Exploring Supplier Shares and Innovative Strategies

  The sector dealing with molecular blood typing and grouping employs advanced immunohaematological techniques to ensure accurate blood transfusion, which is pivotal to patient safety. The market exhibits a growth trajectory, propelled by continuous technological advancements and a rising demand due to an increase in complex surgeries, trauma cases, and prenatal...

  Discover more insights

• Haemophilia: Unravelling Opportunities and Challenges in A & B Types Treatments

  The treatment landscape for Haemophilia A and B, genetic disorders causing impaired blood clotting, is considerably developed yet wavering. Prophylactic factor replacement therapy, the mainstay treatment, is efficacious but fraught with several challenges such as high frequency of infusions, risk of inhibitor development and high cost. Developments in extended half-life...

  Discover more insights

• Hemophilia Treatment Innovations: Exploring Pipeline Reviews and Global Clinical Trials

  The advancement of clinical science has brought an era of novel therapies for hemophilia like gene therapy and bispecific antibodies which are intended to not only treat but potentially cure the condition. A number of new treatments are in the pipeline, providing real hope for enhanced patient care and quality...

  Discover more insights

• Hematologic Disorders: Analyzing Market Trends in Myelofibrosis and Related Syndromes

  The Myelofibrosis market is influenced by several elements. New technologies, research methodologies, and advancements in pharmaceuticals contribute to the sector's dynamism. The increasing prevalence of the disease worldwide is also a significant factor, which leads to a growing demand for effective therapies. Regulatory policies and the role of government in...

  Discover more insights